Amarantus Bioscience Holdings Inc (AMBS)

[Solantey]

MANF comparative study results expected within ten days.

Positive data and the resulting short squeeze will move this above .20.

Any additional press releases will take it higher.

The company is on the radar of a number of big pharma drug companies that are flush with cash and faced with many of their major drugs going over the "patent cliff".

Add a few shares at the bottom before it gaps higher.

The company could be a strong candidate for the 2013 Stock of the Year.